Medisca

What Medisca does

Medisca is a privately held pharmaceutical compounding solutions provider founded in 1989 and headquartered in New York, USA, with 251-500 employees and a global operational footprint spanning North America, Asia Pacific, Europe, South America, the Middle East, and Africa. The company sells a portfolio of over 2,000 products to compounding pharmacies (503A), FDA-registered outsourcing facilities (503B), hospitals, clinics, physicians, contract manufacturers, laboratories, wholesalers, telehealth providers, and the cannabis industry. Its core product lines include active pharmaceutical ingredients (APIs), bases and vehicles, capsules, chemicals, controlled substances, devices, equipment, flavors, colors, oils, and lab supplies, complemented by state-of-the-art mixing and milling technologies, analytical testing capabilities, and formulation support services.

The company's technology stack is centered on physical pharmaceutical compounding infrastructure, standardized operating procedures, and quality-assured ingredient sourcing rather than software platforms. Supporting the product business is a digital ecosystem comprising a B2B e-commerce portal (medisca.com with localized country storefronts), a formula library, BUDs (Beyond Use Date) library, studies library, Compounding 101 educational resources, and a Controlled Substances Ordering System (CSOS) registration platform. The company also operates an education catalog spanning self-paced online learning, seminars, webinars, hands-on lab training, and provider portals, which functions as both a customer acquisition channel and a switching cost driver.

Medisca operates a direct B2B model with enterprise field sales, account-registration-gated pricing, pay-as-you-go billing, and supplementary wholesale distribution. Revenue derives primarily from one-time product sales of pharmaceutical-grade ingredients, with secondary streams from professional services (education, training, consulting, formulation support). The company is privately held with no public ticker, no disclosed funding rounds, and no external investor information available. Recent strategic activity includes the May 2026 partnership with dsm-firmenich for pharmaceutical-grade vitamin APIs, an upcoming launch in Germany via subsidiary Medisca GmbH (offices in Schkopau and Teutschenthal), and the 2022 acquisition of Maxima Pharmaceuticals.

Name

Medisca

Legal name

Medisca Inc.

Website

https://medisca.com

Company type

Private

Founded year

1989

Operating status

Operating

Headcount range

251–500 employees

Short description

Medisca is a privately held pharmaceutical compounding solutions provider founded in 1989, distributing 2,000+ APIs, chemicals, and compounding supplies to pharmacies, outsourcing facilities, hospitals, and healthcare providers globally, supported by formulation, education, and compliance services.

Ownership category

akta.pro rank

Product category

Pharmaceutical Compounding

NAICS

Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Medication Inventory, Procurement & Supply Chain (Pharmacy) (HLACAKAI)

Keywords

• Pharmaceutical compounding
• Active pharmaceutical ingredients
• Compounding pharmacy supplies
• Pharmaceutical formulation support
• Compounding education services

Headquarters

HQ city

Plattsburgh

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Compounding Products: B2B sales of pharmaceutical-grade active pharmaceutical ingredients, compounding bases, vehicles, capsules, chemicals, controlled substances, devices, equipment, flavors, colors, and oils to compounding pharmacies, laboratories, and healthcare providers
2. Education and Training Services: Fee-based educational programs including self-paced online learning, seminars, webinars, hands-on lab training, and provider portals for continuing professional education in pharmaceutical compounding
3. Consulting Services: Specialized consultations and formulation support services for compounding pharmacy professionals

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Medisca is a global supplier of pharmaceutical compounding solutions, offering a portfolio of over 2,000 products including active pharmaceutical ingredients (APIs), bases and vehicles, capsules, chemicals, controlled substances, devices, equipment, flavors, colors, oils, and laboratory supplies. The company complements its physical product catalog with formulation support services, specialized consultations, standard operating procedures, analytical testing, and a comprehensive education catalog covering self-paced online learning, seminars, webinars, and hands-on lab training for compounding pharmacy professionals.

Product overview

Medisca is a global pharmaceutical compounding solutions provider offering over 2,000 products across a unified platform-plus-services model. The core product portfolio includes active pharmaceutical ingredients (APIs) such as pharmaceutical-grade vitamin APIs from the dsm-firmenich partnership, chemical ingredients, bases and vehicles, capsules, controlled substances, devices, equipment, flavors, colors, oils, and lab supplies. The company complements its product offerings with formulation support services, standard operating procedures, specialized consultations, and a comprehensive education catalog (self-paced online learning, seminars, webinars, hands-on lab training, provider portals). Supporting resources include a formula library, BUDs library, studies library, and Compounding 101 educational materials. Medisca serves 503A Pharmacies, 503B Outsourcing facilities, cannabis industry, contract manufacturing, hospitals and clinics, physicians and providers, telehealth, and wholesalers.

Differentiator

Problem solved

Functional benefit

Products and services

• Active Pharmaceutical Ingredients (APIs)

Quantifiable outcome

• Over 2,000 products in portfolio meeting global quality standards
• +1 more outcomes

Named customers9 records

Segments9 records

Ideal customer profiles5 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• dsm-firmenichcoreStrategic or Co-development Partner · 12 May 2026Medisca entered into a strategic partnership with dsm-firmenich to make pharmaceutical-grade vitamin active pharmaceutical ingredients (APIs) available to U.S. compounding professionals. This partnership expands access to ingredients manufactured within European cGMP environments, addressing the growing demand for high-quality APIs in the compounding pharmacy market. The collaboration enables Medisca to offer pharmaceutical-grade vitamin APIs to their network of compounding pharmacies and healthcare providers.

Scale indicators3 records

Recent moves5 records

Expansion highlights6 records

Direct peers

• Letco Medical (LGM Pharma): Letco Medical supplies APIs, excipients, equipment and supplies to compounding pharmacies and 503B outsourcing facilities. It is a direct specialty competitor in the U.S. compounding supply channel.
• Fagron: Fagron is the largest global supplier of pharmaceutical compounding raw materials, APIs, equipment and education services. It directly competes with Medisca across 503A/503B pharmacies, hospitals and outsourcing facilities in the same product categories.
• Spectrum Chemical Mfg. Corp. Spectrum Chemical supplies high-purity chemicals, APIs and laboratory supplies to pharmaceutical, compounding and research customers. It overlaps with Medisca's chemicals, APIs and lab supplies categories for compounding and laboratory buyers.
• PCCA (Professional Compounding Centers of America): PCCA is a leading U.S. supplier of APIs, bases, devices and clinical education for compounding pharmacies. It competes head-to-head with Medisca's 503A pharmacy offering and shares a similar education-and-content go-to-market approach.

Broad incumbents

• McKesson Corporation: McKesson is the largest U.S. pharmaceutical wholesaler and distributor. While it focuses on finished drug distribution rather than compounding APIs, its scale and breadth allow it to compete for hospital and pharmacy wallet share adjacent to Medisca's products.
• Cardinal Health: Cardinal Health distributes pharmaceuticals and medical products to hospitals, pharmacies and healthcare providers. Its at-home solutions and nuclear pharmacy services touch the same end customers Medisca serves via compounding.
• AmerisourceBergen (Cencora): Cencora (formerly AmerisourceBergen) is a top-tier pharmaceutical distributor with global reach. It overlaps with Medisca in wholesale distribution of compounding-related drugs and supplies through its MWI Animal Health and specialty distribution arms.
• Becton, Dickinson and Company (BD): BD manufactures medical devices, injection systems and drug delivery products used by hospitals, compounding pharmacies and 503B outsourcing facilities. It overlaps with Medisca's devices and equipment category for pharmacy compounding workflows.

Others

• dsm-firmenich: dsm-firmenich is Medisca's strategic partner for pharmaceutical-grade vitamin APIs manufactured in European cGMP environments. As a supplier and collaborator (not a competitor), it shapes Medisca's API quality positioning and access to premium ingredients.
• Thermo Fisher Scientific: Thermo Fisher supplies laboratory chemicals, analytical instruments and research consumables that overlap with Medisca's lab supplies and chemicals categories for research and laboratory customers. It is an enabling supplier rather than a direct channel competitor.

Market position

Strengths1 record

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/Medisca

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Medisca